{"entity":{"id":"cellbion","kind":"company","name":"CellBion","aka":["CellBion Co., Ltd.","Cellbion"],"tldr":"A Korean company developing a lutetium-177 prostate cancer therapy of its own, now filed for conditional approval in Korea.","summary":"CellBion was founded in July 2010 and is based at Daehak-ro, Jongno-gu, Seoul, on the Seoul National University cancer laboratory site; it is listed on KOSDAQ under code 308430. Its own description of the business is \"the advancement of Radioligand Therapy (RLT) and Antibody Radionuclide Conjugates (ARC)\".\n\nThe lead asset is lutetium-177 DGUL (pocuvotide) for metastatic castration-resistant prostate cancer, with the matching gallium-68 NGUL diagnostic. The company's pipeline page states that \"conditional approval is anticipated shortly following the completion of Phase 2 trials in Korea\", and Korean trade press reported in 2026 that the conditional-approval application had been submitted to the MFDS. Behind it sit an actinium-225 DGUL programme and an actinium-225 antibody conjugate, both preclinical, and a phase 1 combination of the lutetium agent with pembrolizumab. If approved, it would be Korea's first domestically developed radioligand therapy.","asOf":"2026-09-22","links":[{"label":"CellBion company profile (founded July 2010, Seoul)","url":"http://cellbion.co.kr/?r=reen&c=98/105"},{"label":"CellBion pipeline (177Lu-DGUL, 68Ga-NGUL, 225Ac programmes)","url":"http://cellbion.co.kr/?r=reen&c=99/108"}],"tags":[],"related":["lu-177","ac-225","prostate-mcrpc","psma-pet","ksnm","kirams","ga-68"],"indications":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Seoul, South Korea","country":"KR","companyType":"radiopharma","website":"http://cellbion.co.kr/","ticker":"KOSDAQ: 308430","founded":2010,"stage":"public","investors":[],"funding":[]},"route":"/companies/cellbion/","neighbours":{"isotope":[{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/"},{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/"},{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/"}],"indication":[{"id":"prostate-mcrpc","kind":"indication","name":"Metastatic castration-resistant prostate cancer","route":"/indications/prostate-mcrpc/"}],"technology":[{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"}],"institution":[{"id":"kirams","kind":"institution","name":"Korea Institute of Radiological and Medical Sciences","route":"/institutions/kirams/"},{"id":"ksnm","kind":"institution","name":"Korean Society of Nuclear Medicine","route":"/institutions/ksnm/"}],"journal":[{"id":"nuclear-medicine-and-molecular-imaging","kind":"journal","name":"Nuclear Medicine and Molecular Imaging","route":"/journals/nuclear-medicine-and-molecular-imaging/"}]}}